Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. This is a 55.56 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $53.40 million which missed the analyst consensus estimate of $53.94 million by 1.01 percent. This is a 18.47 percent decrease over sales of $65.49 million the same period last year.